Efficacy and safety of the combination of gilitinib, sonrotoclax and chidamide in the treatment of newly diagnosed AML with FLT3 mutations: A prospective, single-arm, multicenter, exploratory clinical trial

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 02410ab7a45107d5f3c37d3e59082db09acc1f59
First added on: Oct 10, 2026